wellbutrin 150 mg depottabletter
2care4 aps - bupropionhydrochlorid - depottabletter - 150 mg
zarondan 50 mg/ml oral opløsning
essential pharma (m) limited - ethosuximid - oral opløsning - 50 mg/ml
zyban 150 mg depottabletter
glaxosmithkline pharma a/s - bupropionhydrochlorid - depottabletter - 150 mg
ethosuximid "2care4" 50 mg/ml oral opløsning
2care4 aps - ethosuximid - oral opløsning - 50 mg/ml
ethosuximid "paranova" 50 mg/ml oral opløsning
paranova danmark a/s - ethosuximid - oral opløsning - 50 mg/ml
zarondan 50 mg/ml oral opløsning
orifarm a/s - ethosuximid - oral opløsning - 50 mg/ml
solu-cortef 100 mg pulver og solvens til injektionsvæske, opløsning
2care4 aps - hydrocortisonnatriumsuccinat - pulver og solvens til injektionsvæske, opløsning - 100 mg
natriumfusidat "essential pharma (m)" 500 mg pulver og solvens til koncentrat til infusionsvæske, opløsning
essential pharma (m) limited - fusidinsyre - pulver og solvens til koncentrat til infusionsvæske, opløsning - 500 mg
menquadfi
sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokok - vacciner - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.
ethosuximid "nordic prime" 50 mg/ml oral opløsning
nordic prime aps - ethosuximid - oral opløsning - 50 mg/ml